Understanding racial disparities in treatment intensification for hypertension management.
BACKGROUND
Disparities in blood pressure (BP) control may be a function of disparities in treatment intensification (TI).


OBJECTIVE
To examine racial differences in TI, understand modifiable factors that may mediate this relationship, and explore the relative effects of TI and race on blood pressure.


METHODS
Prospective cohort study.


METHODS
Participants were 819 black and white patients with hypertension from an urban, safety-net hospital


METHODS
We sequentially explored the effects of patient race, sociodemographic and clinical characteristics, beliefs about BP/medications, perceptions of provider/discrimination, sodium intake, medication adherence, and provider counseling on TI, performing a series of random effects analyses. To assess the effects of race and TI on BP, we performed linear regressions, using systolic BP (SBP) as the outcome.


RESULTS
Unadjusted analyses and those including sociodemographic and clinical characteristics revealed that black patients had less TI than whites (-0.31 vs.-0.24, p < 0.001), but adjustment for patient beliefs and experiences eliminated the effects of race (beta =-0.02, p = 0.5). Increased patient concerns about BP medications were related to lower TI, as was more provider counseling (beta =-0.06, p = 0.02 and beta = -0.01, p = 0.001, respectively). In the unadjusted analysis, black race was a significant predictor of SBP (134 mm/Hg for blacks vs. 131 mm/Hg for whites, p = 0.009), but when both race and TI were included in the model, TI was a significant predictor of SBP (final SBP 2.0 mm/Hg lower for each additional therapy increase per 10 visits, p < 0.001), while race was not (Blacks 1.6 mm/Hg higher than whites, p = 0.17).


CONCLUSIONS
Improved patient-provider communication targeted towards addressing patient concerns about medications may have the potential to reduce racial disparities in TI and ultimately, BP control.
Manze
Meredith
M
Section of General Internal Medicine, Boston University School of Medicine, Boston, MA, USA. meredith.manze@bmc.org
Rose
Adam J
AJ
Orner
Michelle B
MB
Berlowitz
Dan R
DR
Kressin
Nancy R
NR
D001741:Black or African American / Q000706:statistics & numerical data*; D000959:Antihypertensive Agents / Q000627:therapeutic use*; D001794:Blood Pressure; D005260:Female; D007722:Health Knowledge, Attitudes, Practice; D054625:Healthcare Disparities; D006801:Humans; D006973:Hypertension / Q000188:drug therapy*; D016014:Linear Models; D008297:Male; D055118:Medication Adherence; D008875:Middle Aged; D015999:Multivariate Analysis; D011446:Prospective Studies; D013223:Statistics as Topic; D011795:Surveys and Questionnaires; D044465:White People / Q000706:statistics & numerical data*
D000959:Antihypertensive Agents
N Engl J Med. 1998 Dec 31;339(27):1957-63
9869666
Health Psychol. 1999 Mar;18(2):183-8
10194054
J Gen Intern Med. 2006 Jun;21(6):577-83
16808739
J Gen Intern Med. 2004 Feb;19(2):101-10
15009789
Prog Cardiovasc Nurs. 2000 Summer;15(3):90-6
10951950
JAMA. 2003 May 21;289(19):2560-72
12748199
Ethn Dis. 2007 Summer;17(3):421-6
17985492
N Engl J Med. 2002 Nov 14;347(20):1585-92
12432046
J Gen Intern Med. 2008 Feb;23(2):180-3
18043980
Hypertension. 2004 Oct;44(4):429-34
15326088
J Hum Hypertens. 2009 Mar;23(3):151-9
18784735
Med Care. 2009 Apr;47(4):395-402
19330888
Int J STD AIDS. 2004 Jan;15(1):38-44
14769170
Ann Intern Med. 2001 Nov 6;135(9):825-34
11694107
Circ Cardiovasc Qual Outcomes. 2009 Jul;2(4):385-91
20031865
Ann Intern Med. 2008 May 20;148(10):717-27
18490685
JAMA. 2003 Jul 9;290(2):199-206
12851274
Ethn Dis. 2001 Autumn;11(3):554-63
11572421
N Engl J Med. 2001 Aug 16;345(7):479-86
11519501
Curr Hypertens Rep. 2005 Aug;7(4):244-8
16061041
Hypertension. 2006 Mar;47(3):345-51
16432045
J Gen Intern Med. 2007 Jun;22(6):768-74
17364243
Arch Intern Med. 2005 Oct 10;165(18):2098-104
16216999
Hypertension. 2008 Nov;52(5):818-27
18852389
Am J Hypertens. 2010 Jan;23(1):54-61
19893494